1)      Calcineurin inhibitor alone 5 (11.9)      Calcineurin inhibitor + sMTX 32 (76.2)      Calcineurin inhibitor + MMF 2 (4.8)   Donor (HLA-A, B and DRB1 antigens)        Matched related PB/BM 10/2      Mismatched related PB/BM 3/1      Matched unrelated BM 19      Mismatched unrelated BM 1      Umbilical cord blood 6   allo-HCT: allogeneic hematopoietic cell transplantation; HLA: human leukocyte antigen; sMTX: short-term methotrexate; MMF: buy BMS202 mycophenolate motefil; BM: bone marrow; PB: peripheral blood. Engraftment Neutrophil

Protein Tyrosine Kinase inhibitor engraftment was achieved in 33 (79%) of 42 patients. The median time to neutrophil engraftment was 17 days (range, 9-32). In a total of four of 27 evaluable patients, a platelet count > 20 000/μl was not achieved. In the patients that achieved platelet counts of ≥ 20 000/μl, the median time to platelet engraftment was 33 days (range, 13-99). The cumulative probabilities of neutrophil and platelet engraftment were 79% and 55%, respectively. GVHD Twenty-four of 42 patients developed aGVHD (eight grade I, nine grade II, five grade III, two grade IV). Twelve of 24 evaluable patients developed cGVHD (one limited, 11 extensive). At five years, the cumulative probabilities of aGVHD and cGVHD were 63% and 37%, respectively. NRM A total of eight patients were alive at the time of this analysis, seven in

complete remission (CR). The most common cause of death was disease relapse/progression. Causes of death were disease relapse/progression (n = 27), GVHD (n Abiraterone = 2), sinusoidal obstruction syndrome (SOS) (n = 3), Epstein-Barr virus associated post-transplant lymphoproliferative disorder (n = 1), and adenovirus BVD-523 clinical trial infection (n = 1). Of six patients with CNS lesion, five died of disease relapse/progression (n = 3), GVHD (n = 1) and SOS (n = 1), and one was alive at last follow-up although another HCT was planned due to BM relapse post-transplant.

At five years, the cumulative probability of NRM was 38%. Nine patients died before day 30, and 18 patients died within the first 100 days post-HCT. LFS and OS A total of 22 of 33 evaluable patients attained a CR after the allo-HCT. The median follow-up of survivors was 85 months (range, 24-126 months). The five-year Kaplan-Meier estimates of LFS and OS were 17% and 19%, respectively. Univariable analysis We analyzed the impact of pre- and post-transplant characteristics on OS after allo-HCT. The factors included age at transplant, sex, primary vs. secondary leukemia, cytogenetics at diagnosis, number of BM blasts, donor type, myeloablative vs. reduced-intensity conditioning, and presence or absence of acute and chronic GVHD. Results of univariable analysis for OS are summarized in Table 2. In the univariable analyses of the impact of pre-transplant variables on OS, poor-risk cytogenetics, number of BM blasts (>26%), MDS overt AML and CB as stem cell source were significantly associated with worse prognosis (p = .03, p = .01, p = .02 and p < .001, respectively).